Honasa Consumer approves ₹135 crore acquisition of 58% stake in Fluence Pharma

What Honasa Consumer announced

On 23 June 2026, Honasa Consumer Limited’s board approved the acquisition of Fluence Pharma Private Limited and the incorporation of a wholly‑owned subsidiary, Honasa Health Private Limited. The acquisition targets a 58% equity stake in Fluence Pharma, valued at an enterprise value of approximately ₹135 crore. The remaining 42% equity will be acquired in two tranches over the next 5‑7 years, subject to the satisfaction of standard closing conditions.

"The board approved the acquisition of Fluence Pharma and the formation of Honasa Health Private Limited" – Honasa Consumer Limited, filing to NSE, 23 June 2026.

Fluence Pharma currently offers condition‑specific over‑the‑counter (OTC) supplements under the brands Hair Fact, Skin Fact and Pro Fact. Honasa Health will focus on business‑to‑consumer (B2C) operations in the nutraceutical segment.

Acquisition structure and terms

• Stake acquired now: 58% of Fluence Pharma’s equity via a secondary purchase.
• Valuation: The transaction is priced at an enterprise value of ~₹135 crore. The filing notes that the price is subject to closing adjustments and the usual conditions precedent.
• Future purchases: The balance 42% will be bought in two tranches over a 5‑7 year horizon after the initial closing. No specific pricing or timing for these tranches is disclosed.
• Method of acquisition: The purchase is a secondary transaction, meaning existing shareholders will sell their shares rather than the company issuing new equity.
• Regulatory compliance: The announcement complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30, and the SEBI Master Circular dated 30 January 2026.

Incorporation of Honasa Health Private Limited

The board also approved the creation of Honasa Health Private Limited, a wholly‑owned subsidiary intended to manage the B2C nutraceutical business. While the filing does not disclose capitalisation details for the new entity, it signals Honasa’s strategic intent to expand its footprint in the fast‑growing nutraceutical market, which the company’s presentation (Annexure‑A) estimates to be ₹16,000 crore in size by FY25, growing at an 11% CAGR.

Key facts at a glance

Why this matters for investors

The acquisition gives Honasa immediate exposure to Fluence Pharma’s OTC supplement portfolio, expanding its product range beyond its existing offerings. By securing a controlling 58% stake, Honasa can influence strategic decisions while still leaving room for future integration of the remaining equity. The staged purchase approach spreads cash outlay and risk over several years, aligning with Honasa’s longer‑term growth plan.

The formation of Honasa Health signals a dedicated vehicle for the nutraceutical business, which may improve operational focus, reporting clarity, and potential future financing. However, the filing does not disclose how the acquisition will be funded, nor does it provide details on any debt or equity raise associated with the deal. Consequently, investors should monitor subsequent disclosures for financing terms, any impact on the company’s balance sheet, and the progress of the remaining tranche acquisitions.

Conclusion

Honasa Consumer’s board has cleared a ₹135 crore acquisition of a 58% stake in Fluence Pharma, with a plan to acquire the remaining 42% over the next 5‑7 years. Simultaneously, the company will set up Honasa Health Private Limited to run its B2C nutraceutical operations. The transaction is subject to standard closing conditions, and further details on financing and subsequent tranche pricing are expected in future filings.